TAO Synergies TAOX
NASDAQ TAOX
$4.07 +0.06 (+1.50%)
As of: Sep 9, 2026 · 11:20 AM EDT

TAO Synergies (TAOX) Other Non Operating Income (2022 - 2026)

TAO Synergies' (TAOX) quarterly Other Non Operating Income came in at $995000.0 in Q2 2026, up 1066.02% on a YoY basis from $85333.1 in Q2 2025, and up 160.3% quarter-over-quarter from -$1.6 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Other Non Operating Income (2022 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Other Non Operating Income for 5 consecutive years, with $995000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non Operating Income rose 1066.02% year-over-year to $995000.0; the trailing twelve-month figure through Jun 2026 stood at $5.1 million (up 2031.56% YoY), and the FY2025 full-year result was $5.6 million, up 438.08% from the prior year.
  • Other Non Operating Income climbed to $995000.0 in Q2 2026 per TAOX's latest filing, from -$1.6 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $5.6 million in Q4 2025 and bottomed at -$2.5 million in Q2 2023.
  • Historically, Other Non Operating Income has averaged $467160.0 across 5 years, with a median of $141000.0 in 2024.
  • The sharpest annual moves came in 2025 and 2026: Other Non Operating Income soared 9640.68% in 2025, then slumped 1988.61% in 2026.
  • Over 5 years, Other Non Operating Income stood at $1.8 million in 2022, then slumped by 70.02% to $546000.0 in 2023, then tumbled by 110.81% to -$59000.0 in 2024, then jumped by 9640.68% to $5.6 million in 2025, then tumbled by 82.32% to $995000.0 in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods registered $995000.0, -$1.6 million, and $5.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 212.35 Bn 198.36 Bn 7.24 Bn
2 Gilead Sciences 181.19 Bn 178.01 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.48 Bn 124.62 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.59 Bn 74.60 Bn 3.93 Bn
5 Argenx Se 61.45 Bn 56.27 Bn 1.37 Bn
6 Moderna 54.89 Bn 49.75 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.21 Bn 30.90 Bn 992.69 Mn
8 Biogen 31.38 Bn 30.10 Bn 1.96 Bn
9 Roivant Sciences 29.81 Bn 29.81 Bn 1.16 Mn
10 TAO Synergies 30.41 Mn 30.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 995,000.00
Mar 31, 2026 -1.65 Mn
Dec 31, 2025 5.63 Mn
Sep 30, 2025 106,000.00
Jun 30, 2025 -103,000.00
Mar 31, 2025 -79,000.00
Dec 31, 2024 -59,000.00
Sep 30, 2024 -22,000.00
Jun 30, 2024 141,000.00
Mar 31, 2024 972,000.00
Dec 31, 2023 546,000.00
Sep 30, 2023 969,000.00
Jun 30, 2023 -2.48 Mn
Mar 31, 2023 225,800.00
Dec 31, 2022 1.82 Mn